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A B S T R A C T
This is the ﬁrst multicenter Italian experience with ruﬁnamide as an adjunctive drug in children,
adolescents and adults with Lennox–Gastaut syndrome.
The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian
centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged
between 4 and 34 years (mean 15.9  7.3, median 15.0), were treated with ruﬁnamide for a mean period of
12.3 months (range 3–21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic.
Ruﬁnamidewas added to the baseline therapy at the starting dose of 10 mg/kg bodyweight, evenly divided in
two daily doses and then increased by 10 mg/kg approximately every 3 days up to a maximum of 1000 mg/
day in children aged 4 years with a body weight less than 30 kg. In patients more than 30 kg body weight,
ruﬁnamide could be titrated up to 3200 mg/day.
After amean follow-up period of 12.3months (range 3–21months), the ﬁnalmean dose of ruﬁnamide
was 33.5 mg/kg/24 h (range 11.5–60) if combined to valproic acid, and of 54.5 mg/kg/24 h (range 21.8–
85.6) without valproic acid. The response rate (50% decrease in countable seizures) was 60.5% (26 of 45
patients) in total; 51.1% experienced a 50–99% reduction in seizure frequency and complete seizure
control was achieved in the last 4 weeks follow-up by 9.3% of patients. Two patients (4.7%) had a 25–50%
seizure reduction, while seizure frequency remained unchanged in 13 (30.2%) and increased in 2 (4.7%).
Reliable data for atypical absence seizures and myoclonic seizures were not available, as these are
usually impossible to count.
Ten patients (23.2%) reported adverse side effects, while taking ruﬁnamide. They were generally mild
and transient and most frequently included vomiting, drowsiness, irritalibility and loss of appetite.
In conclusion, ruﬁnamide as an adjunctive therapy reduced the number of drop attacks and major
motor seizures in about 60% of patients with Lennox–Gastaut syndrome and produced only mild or
moderate adverse side effects.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Ruﬁnamide is a structurally triazole-derivative (1-[2,6-diﬂuor-
ophenyl)methyl]-1hydro-1,2,3-triazole-carboxamide) novel anti-
epileptic drug, structurally unrelated to the existing antiepileptic
drugs, and marketed in Italy since the beginning of 2009. Thevier Ltd. All rights reserved.
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sodium-dependent action potential ﬁring.1,2 Ruﬁnamide has a
broad efﬁcacy spectrum in rodent seizure models of epilepsy.3 In
three RCT trials ruﬁnamide was effective and safe for the
adjunctive treatment of partial seizures in adults and adoles-
cents,4,5 as well as for the treatment of generalized seizures
associated with Lennox–Gastaut syndrome (LGS).6
A 3-year open-label follow-up study reports continued
ruﬁnamide effectiveness as adjunctive therapy in patients with
Lennox–Gastaut syndrome.7
Furthermore, a recently published multicenter study from
Europe using observational retrospective data, conﬁrmed ruﬁna-
mide to be effective in children and adults with refractory epilepsy,
including Lennox–Gastaut syndrome.8
Ruﬁnamide was granted orphan drug status in the adjunctive
treatment of Lennox–Gastaut syndrome by the European Medi-
cines Agency (EMEA) and the U.S. Food and Drug Administration
(FDA) in 2004. Additionally, amarketing authorization approval for
use of ruﬁnamide as adjunctive therapy of seizures associatedwith
LGS syndrome in children 4 years and older was granted by the
EMEA in 2007, and by FDA in 2008.
Nonetheless, the number of patients treated with this medica-
tion is still limited, and a larger number of studies are needed to
better establish the role of ruﬁnamide in the overall treatment
algorithm for this syndrome.9
The purpose of this paper is to report on the ﬁrst multicenter
Italian experience with ruﬁnamide as add-on drug in children,
adolescents and adults with Lennox–Gastaut syndrome and
difﬁcult-to control seizures.
2. Materials and methods
Patients were recruited in a prospective, add-on, open-label
treatment study from 11 Italian centers for pediatric and
adolescent epilepsy care. The patients were selected according
to the following criteria: (1) age 4 years and over; (2) Lennox–
Gastaut syndrome refractory to at least three previous antiepilep-
tic drugs (AEDs), alone or in combination; (3) more than one
seizure permonth in the last 6months; (4) use of at least one other
AED, but no more than three, at baseline; (5) informed consent
from parents and/or caregivers, who had to be able administer the
study drug and record seizures in a diary. Moreover, female
patients of child bearing age were required not to be pregnant and
to be using an adequate form of contraception.
Exclusion criteria included progressive neurological or systemic
disease. Patients with signiﬁcantly abnormal liver, kidney and
blood laboratory values were also excluded, as were those who
were considered unlikely to comply with the study requirements.
Besides enrolling ruﬁnamide-naı¨ve subjects, study sites that
had previously started patients on ruﬁnamide had the option of
enrolling patients who had completed at least 6 months of
maintenance treatment and met the study inclusion and exclusion
criteria. This means that some patients could be retrospectively
included.
Pseudo-seizures were excluded by means of video-EEG
recordings and/or long-term monitoring EEGs. CT and MRI were
performed in all cases. The number of the seizures was recorded
by parents and/or caregivers at home and at school. Seizure
frequency, type and duration were recorded in an epilepsy diary
reviewed at each follow-up visit. All seizures were classiﬁed
according to the International League against Epilepsy Revised
Classiﬁcation of Seizures (ILAE Commission, 1981),10 while
diagnostic criteria for Lennox–Gastaut syndrome were based on
the International League Against Epilepsy classiﬁcation (1989) as
follows: (1) polymorphous seizures including tonic–axial, atonic,
and absence seizures (other types such as myoclonic, GTCS, orpartial seizures are frequently associated); (2) EEG abnormal
background activity, slow spike-waves <3 Hz and, often multifo-
cal abnormalities, and bursts of 10 Hz fast rhythms during sleep;
(3) in general, mental retardation.11 There was an initial
observation period of 6months (baseline) that could be shortened
to 3 months if seizures occurred almost daily. After the
observation period, ruﬁnamidewas added to the baseline therapy
at the starting dose of 10 mg/kg body weight, evenly divided in
two daily doses and then titrated by 10 mg/kg per day
approximately every 3 days up to a maximum of 1000 mg/day
in children aged 4 years with a body weight less than 30 kg. If
baseline therapy included valproic acid, ruﬁnamide could be
titrated up to a maximum of 600 mg/day, because of the
signiﬁcantly reduced clearance, especially in children, of ruﬁna-
mide in combination with valproic acid. In patients more than
30 kg body weight, ruﬁnamide could be titrated up to 1800 mg/
day if bodyweightwas comprised between 30.0 and 50.0 kg, up to
2400 mg/day for bodyweight of 50.1 to 70.0 kg, andup to 3200 mg
for body weight of more than 70.1 kg.
During titration and maintenance periods, anticonvulsant drug
daily doses including ruﬁnamide could be changed whenever
necessary depending on clinical and adverse side effects. Rescue
drugs were allowed if necessary. EEG, adverse effects and blood
levels of concomitant anticonvulsant drugs were monitored in all
patients. Patients were followed on a weekly basis during the
titration period, either by means of visits to the clinic or by
telephone. Patients subsequently visited the clinic at 3-month
intervals during the maintenance treatment, with a monthly
follow-up by telephone between visits to the clinic whenever
necessary. Blood chemistry and liver and kidney function were
carefully assessed at each time interval. Parents/caregivers were
informed of the potential clinical adverse effects and to refer any
such side effects to the clinician.
Efﬁcacy was assessed by comparing the frequency of countable
seizures at baseline (4 weeks before ruﬁnamide therapy) with the
frequency in the last 4 weeks of observation.
The response to treatment wasmonitored in terms of reduction
of seizure frequency, in relation to the baseline phase, using the
following categories: (1) seizure control (100% seizure remission);
(2) 50–99% decrease in number of seizures; (3) 25–49% decrease in
number of seizures; and (4)worsenedwhen the seizure rate and/or
severity increased by 25% as compared to baseline period.
The Institutional Review Board from each epilepsy unit
approved the study; no support was received from pharmaceutical
companies.
Statistical evaluation was performed by means of a two-tailed
Wilcoxon Rank test for non-parametric data and the Fisher exact
test. Data were expressed as mean  SD and median values.
Signiﬁcance was set at p < 0.05.
3. Results
Forty-three patients (26 males, 17 females), aged between 4
and 34 years (mean 15.9  7.3, median 15.0), were treated with
ruﬁnamide for a mean period of 12.3 months (range 3–21 months).
Twenty patients were diagnosed as cryptogenic, and 23 as
symptomatic Lennox–Gastaut syndrome (9 brain atrophy, 9 migra-
tion disorder, 4 brain malformation, 1 tuberous sclerosis). Mental
retardation (MR), evaluated before starting ruﬁnamide by Brunet–
Lezine12 or Terman–Merrill13 tests, was present in all patients: mild
MR was detected in 12 patients, moderate in 6, severe in 15, and
profound in 10. Neurological examination at the time of entry
revealed abnormalities in 35/43 patients (81.4%) with minor motor
impairments in 16, hemiparesis in 2, spastic tetraplegia in 11, diplegia
in 1, ataxia in 3, generalized hypotonia in 2. CT/MRI scans showed
abnormal ﬁnding in 23/43 patients (53.5%): brain atrophy (9),
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4–7 4 Seizure free – – C (2.5)





8–12 11 Seizure free 1 (9.1%) C (1) 3 (27.3%) C (2.3) (VPA-LEV)
50–90% 7 (63.6%) C (1) S (6) S (2.2) 3 (VPA-LEV); (VPA-LEV-CNZ); (VPA-LEV-ETS);
(LTG-CLOB); (VPA-ETS)
25–50% 1 (9.1%) C (1) (VPA-FBM-CLOB)
Unchanged 2 (18.2%) S (2) (VPA-CNZ); (VPA-TPM)
Increased –
13–18 20 Seizure free 3 (15%) C (3) 5 (25%) C (2.5) (VPA-LEV-CNZ); (VPA-LTG-CNZ); (PB-FBM-OXC)
50–90% 8 (40%) C (3) S (5) S (2.2) (FBM-OXC); (VPA-FBM); (VPA-LEV-TPM); (VPA-LTG);
(VPA-ETS); (CBZ-PB); (LEV-CLOB); (VPA-LEV-CLOB)
25–50% 1 (5%) C (1) (LEV)
Unchanged 7 (35%) C (4) S (3) (VPA-CBZ-CLOB); (OXC-PB-LEV); (OXC-LTG);
(VPA-FBM-CNZ); (LTG-TPM); (VPA-FMB);
(VPA-PHT)
Increased 1 (5%) S (1) (VPA-ZNS-FBM)
>18 8 Seizure free – 2 (25%) C (3)
50–90% 3 (37.5%) C (1) S (2) S (3) 2 (VPA-LEV-ZNS); (LTG-TPM-CBZ)
25–50% –
Unchanged 4 (50%) C (1) S (3) (LEV-PB-LTG); (VPA-LEV-TPM); (LEV-TPM-PB);
(VPA-LTG-TPM)
Increased 1 (12.5%) S (1) (VPA-CBZ-CNZ)
C, cryptogenic; S, symptomatic; AED, antiepileptic drug; VPA, valproic acid; PB, phenobarbital; CNZ, clonazepam; LTG, lamotrigine; ZNS, zonisamide; OXC, oxcarbazepine;
CBZ, carbamazepine; LEV, levetiracetam; FBM, felbamate; CLOB, clobazam; TPM, topiramate; PHT, phenitoine.
Table 2
Efﬁcacy of ruﬁnamide in patients with cryptogenic or symptomatic Lennox–
Gastaut syndrome.
Cryptogenic Symptomatic
No. of patients (20) No. of patients (23)
Seizure control
100% 4 (20%) –
50–99% 9 (45%) 13 (56.5%)
25–49% 2 (10%) –
Unchanged 5 (25%) 8 (34.8%)
Increased 0 (0%) 2 (8.7%)
Drop-attacks
100% 4 (20%)* 2 (8.7%)*
50–99% 8 (40%)* 6 (26%)*
Tonic seizure
100% 4 (20%)o –
50–99% 4 (20%)o 7 (30.4%)o
Tonic–clonic seizure
100% 2 (10%) –
50–99% 2 (10%) 1 (4.3%)
* p=0.23 at Fisher exact test.
o p=0.43 at Fisher exact test.
G. Coppola et al. / Seizure 19 (2010) 587–591 589disorders of neuronal migration (9), brain malformations (4),
tuberous sclerosis (1). Seizure types, generally associated in a given
patient before the introduction of ruﬁnamide, were classiﬁed as
follows: atypical absences in 14 (32.5%), drop-attacks (atonic and/or
myoclonic) in 35 (81.4%), tonic in 22 (51.2%), tonic–clonic in 12
(27.9%), and complex partial seizures in 6 (20.9%). Seizure frequency
during baseline phase was the following: < 1/day (10); 1–20/day
(33).
Mean age at seizure onset was 2.2  2.1 years (median 1.0).
Mean duration of epilepsy was 13.8  7.9 years (median 12.0). The
mean number of anticonvulsant drugs tried before ruﬁnamide was
7.8  2.0 (median 7.5). A ﬁnal mean dose of ruﬁnamide was 33.5 mg/
kg/24 h (range 11.5–60 mg/kg/24 h) if combined to valproic acid, and
of 54.5 mg/kg/24 h (range 21.8–85.6 mg/kg/24 h) without valproic
acid. All patients received concomitant antiepileptic therapy. Valproic
acid (69.8%), levetiracetam (39.5%), clonazepam (20.9%), and lamo-
trigine (20.9%) were the most commonly used concomitant antiepi-
leptic drugs (Table 1).
3.1. Efﬁcacy
The results are summarized in Table 1. Nine of 43 patients
(20.9%) had an observational period of 3 months; seven of them
discontinued treatment within 1–5 months because of inefﬁcacy
(4) or adverse events (3).
Twenty-six of 43 patients (60.5%) receiving ruﬁnamide as
adjunctive therapy had a 50% seizure reduction in countable
seizures after a mean 12-month observational period (Table 1).
Complete seizure freedom was achieved in four patients (9.3%).
Two patients had a 25–50% seizure reduction, while seizure
frequency remained unchanged in 13 (30.2%) and increased in two
patients (4.7%).
Regarding the seizure type, 20 of the twenty-six responders
(78.9%) had a 50% reduction in drop attacks (six patients were
seizure free), and 15 of 26 responders (57.7%) had a50% decrease
in tonic seizures (four patients were seizure free).Tonic–clonic seizures improved by 50% or more in 5/26
responders (11.6%).
Reliable data for atypical absence seizures and myoclonic
seizures were not available, as these are usually impossible to
count.
There was no statistical difference between the characteristics
of the responders and non-responders with respect to age at
seizure onset, epilepsy duration and age at ruﬁnamide exposure
(p > 0.05 at Wilcoxon Rank Sum test).
Table 2 shows that there is not a signiﬁcant difference as to a
50% seizure reduction between cryptogenic group and symp-
tomatic group (65% vs 56.5%, respectively; p  0.05). Nonetheless,
drop-attacks were to some extent better controlled in the
cryptogenic group (60% vs 34.7%; p = 0.23).
Table 3
Adverse events in LGS patients treated with ruﬁnamide as add-on therapy.
Adverse eventsa No. of patients
(10/43) (23.2%)
Vomiting and /or gastrointestinal disorders 6 (13.5%)
Irritability/aggressiveness 3 (6.9%)
Drowsiness 1 (2.3%)
Skin rash 1 (2.3%)
Decreased appetite 1 (2.3%)
a Associated in some patients.
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Ten patients (23.2%) reported adverse side effects, while taking
ruﬁnamide (Table 3). Vomiting was present in six patients, leading
to drug discontinuation in three patients after 1, 3 and 5 months,
respectively. In these patients seizures were unchanged in two and
increased in one; noteworthy, all three patients were taking
baseline felbamate and valproic acid. In two more patients,
vomiting and/or gastrointestinal disorders were transient, while in
another one vomiting appeared at ruﬁnamide daily dosage of
53.3 mg/kg. In this patient, vomiting promptly disappeared, when
the daily dose was decreased by half. In these patients with
vomiting or nausea the mean dose of ruﬁnamide was 34.4 mg/kg/
day (11.5–56.2 mg), and the mean blood level of valproic acid was
61.5 mg/L (56–78 mg). Drowsiness, decreased appetite, skin rash
and irritability manifested in other ﬁve patients; they were
transient and mild in all cases.
Seizure worsening was reported in 2 of 43 patients (4.6%), both
coming from the symptomatic group, within 1month after starting
ruﬁnamide. Blood levels of concomitant anticonvulsant drugswere
generally not modiﬁed by the addition of ruﬁnamide. All the
patients’ laboratory test values were normal.
4. Discussion
In this prospective, open-label add-on study, ruﬁnamide
signiﬁcantly reduced the overall seizure frequency in approxi-
mately 60% of patients with Lennox–Gastaut syndrome who had
been resistant to at least three previous antiepileptic drugs. This is,
to our knowledge, the ﬁrst multicenter Italian trial with this drug.
In addition, drop attacks, tonic seizures and, to a lesser extent,
tonic–clonic seizures best responded to this therapy. With respect
to seizure etiology, there was a trend to a better response to
ruﬁnamide for drop-attacks in cryptogenic cases, although it was
not statistically signiﬁcant (p = 0.23, at Fisher’s exact test). Because
of their sudden nature and tendency to produce injury, major
seizures (tonic/atonic and tonic–clonic seizures) are easily
identiﬁable by parents or caretakers and represented the main
end-point in the present trial in such a catastrophic syndrome.
The overall response to ruﬁnamide observed in this study is
consistent with that reported in two previous studies conducted in
the US and Europe on children and young adults with Lennox–
Gastaut syndrome.6,8 In the ﬁrst randomized double-blind,
placebo-controlled trial by Glauser et al.,6 the median percentage
reduction in total seizure frequency was greater in the ruﬁnamide
therapy group than in the placebo group (32.7% vs 11.7%,
p = 0.0015). Ruﬁnamide also decreased tonic–atonic seizure
frequency by 42.5% vs 1.4% on placebo.
The other study by Kluger et al.8 was an observational trial
conducted as a collection of retrospective data regarding children
and adults with refractory epilepsy from multiple centres in
Germany and Austria. The response rate in a subset of 31 patients
with LGS was 54.8%; further, 4 of these 31 patients became seizure
free during the study period. Although relative to a study
population including refractory epilepsy syndromes other thanLennox–Gastaut patients, the highest responder rates were
observed for tonic seizures (45%) and drop attacks (47.1%).
Although a new drug therapy may easily lead to transient
improvement in LGS patients, a mean follow-up period of 12.3
months, even if not prolonged, appears quite long to show a
persisting efﬁcacy of adjunctive ruﬁnamide in our responders.
Seemingly, data yielded by Kluger et al.7 on 124 LGS patients
receiving ruﬁnamide in an open-label extension at a median dose
of 1800 mg/day for a mean duration of 432 days, showed that,
during the last 12 months of treatment, 41.0 and 47.9% of patients
had 50% reduction in total and tonic–atonic seizure frequency,
respectively. Accordingly, Kluger et al.14 reported in another series
that 51.6% of patients with Lennox–Gastaut syndrome were still
taking ruﬁnamide after 18 months of follow-up, with a responder
rate of about 35.5%.
Worthy of note is the dose-range of ruﬁnamide’s maximal
efﬁcacy, which in our series was essentially comparable to that
reported by Kluger et al.8
In agreement with pharmacokinetic studies,15 blood levels of
concomitant antiepileptic drugs were not signiﬁcantly modiﬁed
in our patients, thus suggesting that ruﬁnamide’s effects were
not substantially inﬂuenced by concomitantly administered
therapy.
It is noteworthy that seizure worsening on ruﬁnamide was not
reported in either patients with LGS6,8 or partial seizures.5 In three
patients reported by Glauser et al.,6 status epilepticus appeared 13,
20 and 25 days after starting ruﬁnamide therapy, respectively,
leading to drug withdrawal in two patients. In our series, the two
patients out of 43 (4.8%) who had seizure increase, showed the
following clinical features: one 24-year-old male with bilateral
pachygyria developed early seizure worsening whenever a new
antiepileptic drug was added to his baseline drug regimen; a
second one showed seizure increase on ruﬁnamide when
felbamate daily dose was reduced.
So far, seizure worsening on ruﬁnamide is not clearly proven,
although such a possibility cannot be ruled out, and further
experience with this drug needs to be done.
As shown in Table 1, no clear relationship emerged between the
clinical response to ruﬁnamide and any seizure etiology or baseline
AED treatment in the different age groups.
Six patients with cryptogenic LGS underwent implantation of a
vagus nerve stimulator (VNS) (5) or callosotomy (1), with no
signiﬁcant results on seizure frequency prior to receiving
ruﬁnamide. Two of these patients, both on VNS, showed a 50%
reduction in drop attacks on ruﬁnamide after a follow-up period of
4 and 9 months, respectively.
With respect to tolerability, our series disclosed adverse side
effects probably linked to ruﬁnamide adjunctive treatment in
about 20% of patients, much in keeping with what reported by
Glauser et al.6 and Kluger et al.8 They frequently appeared early
after starting drug titration, and most commonly included
vomiting, drowsiness and loss of appetite. In our experience,
persistent vomiting led to drug discontinuation in three patients,
similarly to what happened in four patients of Kluger et al.8 and in
six patients of Glauser et al.6 Interestingly, all patients were taking
valproic acid together with ruﬁnamide, suggesting a potential risk
of this association to expose to such an adverse event. Unfortu-
nately, the number of patients is too small to draw any conclusion.
Worthy of note is that serious adverse effects have not been
reported so far.
In conclusion, in our experience ruﬁnamide reduced seizure
frequency in children and young adults with Lennox–Gastaut
syndrome, and it was particularly effective against drop-attacks
and tonic seizures. Reliable data for atypical absence seizures and
myoclonic seizures were not available, as these are usually
impossible to count.
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population. This trial seems to conﬁrm what emerged in a few
previous studies, although further experience is warranted to gain
better understanding of the efﬁcacy of ruﬁnamide both in the long
term and in the treatment of well-deﬁned epileptic encephalopa-
thies other than Lennox–Gastaut syndrome.
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